Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer
Shots:
• Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18
• CT-P16 extended to Phase III as planned by submission of application to National Authority of Medicines and Health Products- I.P. (Infarmed) of Portugal
• Celltrion has plan to conduct Phase III clinical trial for CT-P16 in about 150 sites with 20 countries starting with Portugal- Europe- Asia and South America
Ref: Celltrion | Image: Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com